Filter Results
Conditions
Locations
Treatment Type
Trial Phase
Trial Status
Paid Participation
Clear All
121 Prostate Cancer Trials near Tampa, FL
Power is an online platform that helps thousands of Prostate Cancer patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.
ACE-232 for Prostate Cancer
Tampa, FloridaThis is an open label, phase I, multi-center study aiming to assess the safety and tolerability in patients with metastatic castration resistant prostate cancer (mCRPC).
No Placebo Group
Trial Details
Trial Status:Not Yet Recruiting
Trial Phase:Phase 1
Age:18+
Sex:Male
67 Participants Needed
High Intensity Focused Ultrasound for Prostate Cancer
Gainesville, FloridaThis study will investigate the efficacy of focal high intensity focused ultrasound (HIFU) in patients with localized radiorecurrent prostate cancer. This study will also investigate the change in participant quality of life after HIFU therapy as compared to before HIFU therapy.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:18+
Sex:Male
Key Eligibility Criteria
Disqualifiers:Inflammatory Bowel Disease, Metastatic, Others
Must Not Be Taking:Hormone Therapy
25 Participants Needed
This is a multicenter, prospective, randomized clinical trial that aims to assess the safety and efficacy of Aquablation Therapy in men with low-risk to intermediate to high-risk localized prostate cancer who are candidates for, or have opted for, prostatectomy. Participants will be randomized to either Aquablation Therapy or radical prostatectomy and followed up to 10 years.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:45+
Sex:Male
Key Eligibility Criteria
Disqualifiers:Other Cancer, Cognitive Impairment, Others
Must Not Be Taking:Anticoagulants, Antiplatelets
280 Participants Needed
Androgen Deprivation + Docetaxel for Prostate Cancer
Tampa, FloridaThis is a prospective single center phase IIa open label nonrandomized study, which aims to test the hypothesis that the duration of castration sensitive phase of stage IV prostate cancer can be prolonged with adaptive androgen deprivation therapy (ADT) and Docetaxel.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:18+
Sex:Male
Key Eligibility Criteria
Disqualifiers:Liver Metastases, Brain Metastases, Others
Must Not Be Taking:TAK-700, Abiraterone
25 Participants Needed
OP-3136 for Cancer
Sarasota, FloridaThis is a first-in-human, open-label, multicenter phase 1 study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of OP-3136, a lysine acetyltransferases 6A and 6B (KAT6A/B) inhibitor, in participants with advanced solid tumors.
This study consists of 2 parts: a dose escalation part (Part 1) and dose expansion part (Part 2).
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:CNS Metastases, Cardiac Disease, Others
Must Be Taking:Endocrine Therapy, CDK4/6 Inhibitor
90 Participants Needed
Xaluritamig vs Other Treatments for Prostate Cancer
Orlando, FloridaThe main objective of the study is to compare overall survival in participants receiving xaluritamig versus investigator's choice (cabazitaxel or second androgen receptor-directed therapy \[ARDT\]).
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:18+
Sex:Male
Key Eligibility Criteria
Disqualifiers:CNS Metastasis, Unresolved Toxicities, Others
Must Be Taking:Androgen Deprivation
675 Participants Needed
SpaceIT Hydrogel System for Prostate Cancer
Orlando, FloridaTo evaluate the safety and effectiveness of the SpaceIT™ Hydrogel System in patients undergoing External Beam Radiotherapy (EBRT) for the treatment of prostate cancer.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:18+
Sex:Male
Key Eligibility Criteria
Disqualifiers:Metastatic Disease, Other Cancers, Others
230 Participants Needed
Darolutamide + Relugolix for Prostate Cancer
Orlando, FloridaThe goal of this clinical trial is to determine the safety and feasibility of a new combination of darolutamide and relugolix as neoadjuvant therapy preceding radical prostatectomy (RP) for high-risk prostate cancer (PCa) in adult males.
Stay on current meds
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:18+
Sex:Male
Key Eligibility Criteria
Disqualifiers:Stroke, Myocardial Infarction, Angina, Others
Must Not Be Taking:Chemotherapy, Radiotherapy, Antivirals, Others
30 Participants Needed
PF-06821497 + Enzalutamide for Prostate Cancer
Bradenton, FloridaPfizer MEVPRO-1 (C2321014) is a randomized, open-label, multi-center clinical trial evaluating whether combining the study medicine (PF-06821497) with enzalutamide is safe and effective compared to physician's choice of either second-line androgen receptor (AR) directed therapy with enzalutamide or docetaxel (chemotherapy) for treating metastatic castration-resistant prostate cancer (mCRPC) after progression on prior abiraterone acetate treatment.
The primary objective of this clinical trial is to assess the radiographic progression free survival (rPFS) of the combination of PF-06821497 plus enzalutamide versus physician's choice of enzalutamide or docetaxel.
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:18+
Sex:Male
Key Eligibility Criteria
Disqualifiers:Cardiovascular Disease, Brain Metastasis, Others
Must Not Be Taking:Chemotherapy, ARSi, PARP, Others
600 Participants Needed
Sacral Neuromodulation for Overactive Bladder
Bradenton, FloridaTo assess the post-market clinical outcomes of the Axonics SNM System for treatment of overactive bladder in male patients.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:18 - 75
Sex:Male
Key Eligibility Criteria
Disqualifiers:Neurological Conditions, Uncontrolled Diabetes, Others
150 Participants Needed
PET Scan Agent for Prostate Cancer
Orlando, FloridaFlotufolastat F-18, sold under the brand name Posluma, is a radioactive diagnostic agent for use with positron emission tomography (PET) imaging for prostate cancer.
The research is being done to study the capability of 18F-rhPSMA-7.3 (flotufolastat F-18) PET scan to detect prostate cancer when there are very low levels of Prostate-Specific Antigen (PSA) following previous radical prostatectomy surgery.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:18+
Sex:Male
Key Eligibility Criteria
Disqualifiers:X-ray Contrast, Other PET Radiotracer, Others
Must Not Be Taking:Androgen Deprivation Therapy
30 Participants Needed
ALTA2618 for Cancer
Sarasota, FloridaThe purpose of this study is to characterize the safety and tolerability of ALTA2618 in adults with AKT1 E17K-mutant advanced solid tumors.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:KRAS, NRAS, HRAS, BRAF, Others
Must Not Be Taking:PI3K Inhibitors, MTOR Inhibitors
110 Participants Needed
MOMA-313 + Olaparib for Solid Tumors
Lake Mary, FloridaThis Phase 1, multi-center, open-label, dose escalation and dose optimization study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and preliminary clinical activity of MOMA-313 administered orally as a single agent or combination therapy in patients with homologous recombinant deficient solid tumors.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Cardiovascular Disease, CNS Metastasis, Others
Must Be Taking:PARP Inhibitors
158 Participants Needed
APL-5125 for Colorectal Cancer
Sarasota, FloridaThis is an open-label, Phase 1/2 study to determine the safety, tolerability, and efficacy of APL-5125 for the treatment of selected locally advanced or metastatic solid tumors with particular focus on Colorectal carcinoma (CRC).
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Brain Metastases, Angina, Infection, Others
Must Be Taking:Fluoropyrimidine, Oxaliplatin, Irinotecan, Others
100 Participants Needed
DCC-3084 for Cancer
Orlando, FloridaThis is a multicenter, Phase 1/2 clinical trial to evaluate DCC-3084 alone or in combination with other cancer therapies in participants with advanced cancers. Module A will enroll participants with advanced/metastatic solid tumors. Additional modules exploring other cancers may be added to the master protocol at a later date. Each module will be conducted in 2 parts: Part 1 (Dose Escalation) and Part 2 (Dose Expansion).
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Pregnancy, Cardiac Issues, Recent Surgery, Others
Must Not Be Taking:BRAF Dimer Inhibitors
140 Participants Needed
ISM3091 for Solid Tumors
Tampa, FloridaThis trial is testing a new drug called XL309, either by itself or with another drug called olaparib. It targets people with advanced solid tumors to see if the drug can stop or slow down cancer growth. Researchers are also checking if combining XL309 with olaparib makes it more effective. Olaparib is a type of drug approved for treating various cancers, including ovarian and breast cancer, particularly in patients with certain genetic conditions.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Brain Metastases, Cardiovascular Disease, Others
Must Not Be Taking:Antibody Therapy, Chemotherapy
425 Participants Needed
Copper PET Imaging for Prostate Cancer
Tampa, FloridaThis is a prospective, open-label Phase 3 study to evaluate copper Cu 64 PSMA I\&T injection for PET/CT imaging in patients with newly diagnosed unfavorable intermediate high-risk, high-risk or very high-risk prostate cancer.
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:18+
Sex:Male
Key Eligibility Criteria
Disqualifiers:Interventional Trial, Hypersensitivity, Others
Must Not Be Taking:Androgen Deprivation, Chemotherapy
323 Participants Needed
Copper PET Imaging for Recurrent Prostate Cancer
Tampa, FloridaThis is a prospective, open-label Phase 3 study to evaluate copper Cu 64 PSMA I\&T injection for PET/CT imaging in patients with recurrent prostate cancer after radical prostatectomy or radiation therapy.
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:18+
Sex:Male
235 Participants Needed
AZD0754 for Prostate Cancer
Tampa, FloridaThe purpose of this study is to evaluate the safety, tolerability, and antitumour activity of AZD0754 CAR T-cell therapy in participants with metastatic prostate cancer.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:18+
Sex:Male
Key Eligibility Criteria
Disqualifiers:Brain Metastases, Autoimmune Disorders, Others
Must Be Taking:Androgen Deprivation Therapy
60 Participants Needed
BG-68501 + Fulvestrant for Breast Cancer
Lake Mary, FloridaThis study is a first-in-human (FIH), Phase 1a/1b study of BG-68501, a cyclin-dependent kinase-2 inhibitor (CDK2i), to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-68501 in participants with advanced, nonresectable, or metastatic solid tumors as monotherapy and in combination with fulvestrant with or without BGB-43395, a selective CDK4 inhibitor, in adults with hormone receptor positive (HR+)/human epidermal growth factor receptor 2 negative (HER2-) breast cancer (BC). The study will also identify a recommended dose for expansion (RDFE) for BG-68501 as monotherapy and in combination for subsequent disease directed studies.
The study will be conducted in 2 parts: Part 1 (dose escalation and safety expansion) and Part 2 (dose expansion).
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Uncontrolled Diabetes, Brain Metastasis, Others
Must Be Taking:GnRH Agonists
138 Participants Needed
ABBV-969 for Prostate Cancer
Orlando, FloridaProstate cancer has the second highest incidence rate and is the fifth leading cause of cancer-related deaths among men worldwide. The purpose of this study is to assess safety, pharmacokinetics, and efficacy of ABBV-969 as a monotherapy.
ABBV-969 is an investigational drug being developed for the treatment of metastatic castration-resistant prostate cancer (mCRPC). There are parts to this study. Participants will receive ABBV-969 as a single agent at different doses. Approximately 140 adult participants will be enrolled in the study across sites worldwide.
In part 1 (dose escalation), ABBV-969 will be intravenously infused in escalating doses as a monotherapy. In part 2, multiple doses will be selected from Part 1 and mCRPC participants will be assigned to one of these doses in a randomized fashion to determine the recommended Phase 2 dose. The estimated duration of the study is up to 3 years.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic and may require frequent medical assessments, blood tests, and scans.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Other Active Malignancy, Interstitial Lung Disease, Others
Must Be Taking:Novel Hormonal Agents
140 Participants Needed
LY4101174 for Solid Tumors
Orlando, FloridaThe purpose of this study is to find out whether the study drug, LY4101174, is safe, tolerable and effective in participants with select advanced or metastatic solid tumors. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-expansion). The study will last up to approximately 4 years.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:CNS Metastases, Hypercalcemia, Diabetes, Cardiovascular Disease, Others
490 Participants Needed
Modified Immune Cells for Prostate Cancer
Tampa, FloridaThis is a phase 1 single center clinical trial for patients with end stage Metastatic Castration Resistant Prostate Cancer who have progressed through standard of care treatment options and are on zoledronate for bone metastases. This clinical trial includes a dose-escalation phase and dose-expansion phase to assess the safety and preliminary efficacy of treatment with autologous T cells genetically modified to express Prostate stem cell antigen.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:18+
Sex:Male
Key Eligibility Criteria
Disqualifiers:Hepatitis, HIV, Heart Disease, Others
Must Be Taking:Zoledronic Acid
30 Participants Needed
VIO-01 for Recurrent Cancer
Lake Mary, FloridaThis trial is testing a new drug called VIO-01 to see if it can help treat certain types of advanced cancers with specific genetic mutations. The study will check how safe the drug is, how well the body absorbs it, and its effects on the tumors.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:18+
Sex:All
165 Participants Needed
Opevesostat + Hormone Therapy for Prostate Cancer
Fort Myers, FloridaThis trial is testing a new drug called opevesostat for advanced prostate cancer patients who don't respond to usual care. The drug aims to stop the cancer from growing and spreading, potentially helping patients live longer.
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Gastrointestinal Condition, Diabetes, Cardio/cerebro-vascular, Others
Must Be Taking:Hormone Replacement Therapy
1500 Participants Needed
ONC-392 + Lutetium for Prostate Cancer
Tampa, FloridaIn this Phase 2 study, mCRPC patients with PSMA positive scans who progressed on prior ARTA and up to 2 lines of taxanes, and are naïve to lutetium Lu 177 vipivotide tetraxetan, will be enrolled. The study is open-label, randomized with active control, multi-center study.
No Placebo Group
Prior Safety Data
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:18+
Sex:Male
Key Eligibility Criteria
Disqualifiers:CNS Metastases, Active Hepatitis, Others
Must Be Taking:Androgen-deprivation Therapy
141 Participants Needed
AZD5305 for Prostate Cancer
Saint Petersburg, FloridaThis trial is testing a new drug called Saruparib combined with hormone treatment in adults with prostate cancer that has spread but still responds to hormones. The drug aims to stop cancer cells from repairing themselves, potentially slowing down the disease.
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:18+
Sex:Male
Key Eligibility Criteria
Disqualifiers:MDS/AML, Bleeding Predisposition, Severe Cytopenia, Others
Must Be Taking:GnRH Analogues
1800 Participants Needed
BMS-986460 for Prostate Cancer
Sarasota, FloridaThis trial is testing a new drug called BMS-986460 to see if it is safe and effective for men with advanced prostate cancer that doesn't respond to hormone treatments. The goal is to find out if the drug can help control the cancer's growth and spread.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:18+
Sex:Male
Key Eligibility Criteria
Disqualifiers:Brain Metastases, Cardiac Disease, Others
Must Be Taking:Androgen Deprivation
90 Participants Needed
Lorigerlimab + Docetaxel for Prostate Cancer
Orlando, FloridaThis trial is testing whether adding lorigerlimab to standard treatments (docetaxel and prednisone) can slow down prostate cancer that has spread and is not responding to hormone therapy. Lorigerlimab helps the immune system fight cancer, while docetaxel kills cancer cells, and prednisone manages side effects. About 150 patients will participate, with some receiving the new combination and others receiving just the standard treatment.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:18+
Sex:Male
154 Participants Needed
DB-1311 for Advanced Cancer
Celebration, FloridaThis trial tests a new drug, DB-1311, in patients with advanced solid tumors. It aims to find the safest and most effective dose and then confirm its safety and effectiveness in more patients.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Heart Failure, Lung Diseases, Infections, Others
Must Not Be Taking:B7-H3 Therapy, Topoisomerase Inhibitors
610 Participants Needed
Page 1 of 5+
Frequently Asked Questions
How much do Prostate Cancer clinical trials in Tampa, FL pay?
Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.
How do Prostate Cancer clinical trials in Tampa, FL work?
After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Prostate Cancer trials in Tampa, FL 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in Tampa, FL for Prostate Cancer is 12 months.
How do I participate in a study as a "healthy volunteer"?
Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in Tampa, FL several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.
What does the "phase" of a clinical trial mean?
The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.
Do I need to be insured to participate in a Prostate Cancer medical study in Tampa, FL ?
Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.
What are the newest Prostate Cancer clinical trials in Tampa, FL ?
Most recently, we added ACE-232 for Prostate Cancer, High Intensity Focused Ultrasound for Prostate Cancer and Aquablation Therapy vs Radical Prostatectomy for Prostate Cancer to the Power online platform.